Actinium Pharmaceuticals (NYSE:ATNM) PT Lowered to $4.00

Actinium Pharmaceuticals (NYSE:ATNM) had its price target reduced by HC Wainwright from $50.00 to $4.00 in a report released on Tuesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q3 2024 earnings at ($0.36) EPS, Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.36) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at ($0.92) EPS, FY2027 earnings at ($1.03) EPS and FY2028 earnings at ($1.12) EPS.

Other equities analysts have also recently issued reports about the company. Maxim Group dropped their target price on Actinium Pharmaceuticals from $30.00 to $5.00 and set a buy rating for the company in a report on Tuesday. Stephens initiated coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They set an overweight rating and a $25.00 price objective for the company. Cantor Fitzgerald restated an overweight rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. Finally, StockNews.com cut shares of Actinium Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, August 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $11.43.

Actinium Pharmaceuticals Price Performance

ATNM stock traded down $0.36 during midday trading on Tuesday, hitting $2.05. The stock had a trading volume of 890,374 shares, compared to its average volume of 484,717. The stock has a market cap of $61.06 million, a P/E ratio of -1.19 and a beta of 0.20. Actinium Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. Equities research analysts anticipate that Actinium Pharmaceuticals will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Sanders Morris Harris LLC acquired a new stake in shares of Actinium Pharmaceuticals in the first quarter valued at approximately $78,000. Vanguard Group Inc. increased its stake in shares of Actinium Pharmaceuticals by 6.0% in the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after buying an additional 82,113 shares during the period. Virtu Financial LLC raised its position in shares of Actinium Pharmaceuticals by 319.2% during the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after acquiring an additional 62,459 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Actinium Pharmaceuticals by 28.3% during the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after acquiring an additional 19,035 shares during the period. Finally, Rhumbline Advisers boosted its holdings in Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after acquiring an additional 7,525 shares during the last quarter. 27.50% of the stock is owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.